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Introduction: Brugada syndrome (BrS) is considered a primary electrical disease.
However, morphological abnormalities have been reported and localized arrhythmogenic
right ventricular (RV) dysplasia/cardiomyopathy (ARVD/C) may mimic its phenotype,
raising the question of an overlap between these two conditions and making difficult
the therapeutic management of patients with borderline forms. The main objective
of this study was to assess prospectively the prevalence of BrS and ARVD/C on the
basis of international criteria, in patients with BrS-ECG and normal echocardiography,
looking for a potential overlap between the two pathologies. The secondary objectives
were to describe and quantify angiographic structural alterations, hemodynamics,
electrophysiology, and genetics in the setting of BrS-ECG. Materials and Methods:
Hundred and fourteen consecutive patients matched in age underwent prospectively
cardiac catheterization and quantitative biventricular contrast angiography to rule out
a structural heart disease. Fifty-one patients with a BrS-ECG (BrS group, 7 F, 44M,
43 ± 11 y) had a spontaneous or ajmaline-induced BrS coved type ECG. For angiographic
comparison, 49 patients with localized ARVD/C but without ST segment elevation
in the right precordial leads (14 F, 35M, 39± 13 y) were also studied. They fulfilled
international ESC/WHF 2000 criteria and presented angiographic localized forms, mainly
confined to hypokinetic anteroapical zone (characterized by trabecular dysarray and
hypertrophy), and/or diaphragmatic wall, thus resulting in RV normal volumes and
preserved systolic function. These two populations were also compared with 14 control
patients (7 F, 7M, 38 ± 16 y). Among BrS group, we identified three main angiographic
phenotypes: BrS group I = patients with normal RV (n = 15, 29%); BrS group II =
patients with segmental RV wall motion abnormalities but no structural arguments for
ARVD/C (n = 26, 51%); BrS group III = patients with localized abnormalities suggestive
of focal ARVD/C (n = 10, 20%). Results: Among BrS group, 34/51 patients (67%)
fulfilled BrS HRS/EHRA 2005 criteria. Nineteen (37%) were symptomatic for aborted
sudden death, agonal nocturnal respiration or syncope. Ventricular stimulation was
positive in 14 patients (28%). Angiography showed RV abnormalities in 36/51 patients
(71%) of BrS group (BrS groups II and III). Late potentials were present in 73% (100%
sensitivity and NPV for an angiographic ARVD/C, but poor specificity and PPV, both
37%). In BrS group III, 8/10 patients (16% of BrS patients) finally fulfilled international
ESC/WHF 2000 ARVD/C criteria and 5/10 (10% of BrS patients) fulfilled BrS diagnostic
criteria. An overlap was observed in 4 patients (8% of BrS patients) who fulfilled both
ARVD/C and BrS criteria. Among the 45 genotyped patients, only one presented a
SCN5A mutation, whereas a TRPM4 mutation was found in another patient. Both
belonged to BrS group II. MOG1 gene analysis was negative for all patients, as
were PKP2, DSP, DSG2, and DSC2 analyzes performed in BrS group III. Conclusions:
Seventy-one percent of patients with a BrS-ECG had abnormal RV wall motion and 16%
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had structural alterations corresponding to localized (anteroapical and/or diaphragmatic)
ARVD/C. Moreover, 8% of BrS-ECG patients fulfilled both BrS and ARVD/C criteria. Our
results support the hypothesis of an overlap between BrS and localized forms of ARVD/C.
Conversely, genetic screening was poorly contributive for both diseases in the present
series.
Keywords: Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, overlap, contrast angiography,
genetic testing
INTRODUCTION
Brugada syndrome (BrS) predisposes to an increased risk of sud-
den cardiac death (SCD) due to ventricular fibrillation (VF)
in apparently normal hearts (Brugada and Brugada, 1992). Its
diagnostic criteria have been described in the second consen-
sus conference (Wilde et al., 2002; Antzelevitch et al., 2005),
where experts emphasized the need for exclusion of an organic
heart disease, particularly an arrhythmogenic right ventricular
(RV) dysplasia/cardiomyopathy (ARVD/C), before establishing
the diagnosis of BrS. However, morphological assessment has
been limited to echocardiography in most studies and has not
been yet codified. Moreover, several authors showed evidence
for structural, dynamic (Martini et al., 1989; Takagi et al., 2001;
Papavassiliu et al., 2004), and histological (Martini et al., 1989;
Corrado et al., 1996, 2001; Frustaci et al., 2005) RV abnormal-
ities in patients with typical BrS. Brugada ECG pattern (BrS-
ECG) indeed has been unmasked by ajmaline drug-challenge
in 16% of 55 ARVD/C patients (Peters et al., 2004), and sev-
eral authors made the hypothesis of an overlap between BrS and
ARVD/C (Perez Riera et al., 2005), raising the difficult question
of therapeutic management of patients with borderline forms.
Two recent publications (Frustaci et al., 2005; Kim et al., 2006)
showed that the “BrS” phenotype was not specific of one dis-
ease but could be the result of early, i.e., localized, organic
abnormalities, underdiagnosed by echocardiography or MRI but
revealed by invasive contrast angiography (microaneurysms or
ARVD/C) or by endomyocardial biopsies (myocarditis, ARVD/C,
cardiomyopathy).
On one hand, SCN5A mutation accounts for only 15–25%
of patients with BrS (Ackerman et al., 2011), with an auto-
somal dominant inheritance (Chen et al., 1998). Other muta-
tions have been described but appear mostly private and
HRS/EHRA guidelines only recommend to restrict genetic test-
ing to SCN5A in BrS (Ackerman et al., 2011). On the other
hand, six genes (PKP2 = plakophillin-2, DSP = desmoplakin,
DSG2 = desmoglein-2, JUP = junctional plakoglobin, TGFβ3 =
Transforming Growth Factor-β3, RyR2 = cardiac Ryanodin
Receptor-2) and 12 loci have been identified in ARVD/C so far,
Abbreviations: BrS, Brugada Syndrome; BrS-ECG, Brugada Syndrome ECG
pattern; SCD, Sudden Cardiac Death; VF, Ventricular Fibrillation; ARVD/C,
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy; RV/LV, Right/Left
Ventricle; PPV/NPV, Positive/Negative Predictive Values; RAO/LAO, Right/Left
Anterior Oblique (projection); EF, Ejection Fraction; TAPSE, Tricuspid Annulus
Plane Systolic Excursion; SA-ECG, Signal Averaged-Electrocardiogram; PVS,
Programmed Ventricular Stimulation; RVOT, Right Ventricular Outflow Tract;
VT, Ventricular Tachycardia; MRI, Magnetic Resonance Imaging; EDVi/ESVi, End
Diastolic Volume index/End Systolic Volume index; SI, Stroke Index.
accounting for 30–70% of cases (Basso et al., 2006; Corrado and
Thiene, 2006; Pilichou et al., 2006; Van Tintelen et al., 2006;
Sen-Chowdhry et al., 2007a,b), with an autosomal dominant
inheritance in half of cases (Hamid et al., 2002) and with a
tropism for desmosomal proteins.
The main objective of the present study was to look for a
potential overlap between BrS and ARVD/C by assessing prospec-
tively the prevalence of these two pathologies in patients pre-
senting in daily practice with a typical BrS-ECG and a normal
echocardiography. For this purpose, we used international cri-
teria (HRS/EHRA 2005 criteria for BrS; ESC/WHF 2000 crite-
ria for ARVD/C) (McKenna et al., 1994; Corrado et al., 2000;
Antzelevitch et al., 2005) and quantitative contrast angiography
of the RV which is considered a gold standard for ARVD/C
diagnosis, particularly in localized forms (Hébert et al., 2004).
The secondary objectives were to describe and quantify angio-
graphic structural alterations, hemodynamics, electrophysiology,
and genetics in the setting of BrS-ECG.
MATERIALS AND METHODS
STUDY POPULATION
We conducted a prospective andmonocentric study involving 114
patients who were matched in age and consecutively explored in
our catheterization laboratory fromApril 2001 to July 2006 to rule
out a structural heart disease. Invasive studies were performed
after having obtained the written consent of each patient.
The population under study comprised two groups of patients
and a control group: First, 51 patients (BrS group) were included
because of a type 1 (coved-type) BrS-ECG, either spontaneously
(n = 19) or during ajmaline test (performed in 41 patients),
according to the criteria defined in the second consensus confer-
ence report (Antzelevitch et al., 2005). They had also a normal
echocardiography. Second, 49 consecutive patients with localized
ARVD/C and without ST segment elevation in the right precor-
dial leads were also studied for angiographic comparison. All
fulfilled ESC/WHF 2000 criteria for ARVD/C (McKenna et al.,
1994; Corrado et al., 2000) and presented angiographic local-
ized forms, mainly confined to hypokinetic anteroapical zone
(characterized by trabecular dysarray and hypertrophy), and/or
diaphragmatic wall, thus resulting in RV normal volumes and
preserved systolic function [particularly RVEF ≥ 35% and tricus-
pid annulus plane systolic excursion (TAPSE) ≥14mm]. Third,
these two populations were compared with 14 control patients
matched in age and consecutively recruited during the same
period.
Among BrS group, we identified three main phenotypes
(Figure 1): (1) BrS group I (or “pure” BrS) corresponding to
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FIGURE 1 | Right ventricular (RV) angiographic contours in a 45◦ right
anterior oblique (RAO 45◦) projection and cineangiographic classification
of BrS group, according to qualitative analysis of image-recordings and
to quantitative analysis of right ventricular segmental excursion
analysis. BrS group I: normal RV (patient 32); BrS group II: patients with
BrS-ECG and segmental RV wall motion abnormalities but without arguments
for ARVD/C (patient 40: anterior RV akinesia, apical, inferior and subtricuspid
hypokinesia, normal TAPSE, and crista supraventricularis shortening); and BrS
group III: patients with BrS-ECG and angiographic abnormalities compatible
with ARVD/C (patient 42: anteroapical akinesia, trabecular disarray and
hypertrophy, end systolic polycyclic images). For each contour, the segmental
excursions between diastole and systole are expressed in purple characters
(from top to bottom: number of analyzed chords for each segment; mean
segmental excursion in mm; standard deviation from normal).
patients with BrS-ECG with strictly normal RV; (2) BrS group
II corresponding to patients with BrS-ECG and segmental RV
wall motion abnormalities but without arguments for ARVD/C;
and (3) BrS group III corresponding to patients with BrS-
ECG and angiographic structural abnormalities compatible with
ARVD/C. For all of them, underlying structural cardiac abnor-
malities had been excluded previously by physical examination,
chest X-ray, 2-dimensional echocardiography, and by stress-ECG
when appropriate. All patients had normal serum [K+] and
[Ca2+], troponin Ic, C-Reactive Protein, and TSHus at the time of
diagnosis.
Control patients (7 females, 7 males) had been explored con-
secutively during the same period without medication in our unit
for atypical chest pain associated with a modified stress-ECG
(10 patients) or persistant suspicion of pulmonary embolism
despite normal scintigraphy, finally excluded by pulmonary con-
trast angiography (4 patients). All had normal pressures, RV and
LV volumes and coronary angiograms. Quantitative data con-
cerning their hemodynamics and segmental excursion were used
to define normal values and reference nomograms for segmental
excursion [in both 45◦ right anterior oblique (RAO) and left
anterior oblique (LAO) projections for each ventricle].
Ajmaline was administered under careful monitoring (1mg/kg
body weight, at a rate of 1mg/s with a maximal dose of 100mg).
Patients were excluded if a QRS widening ≥30% occurred even
associated with a coved-type ECG, unless the type 1 pattern
remained present in two right precordial leads (V1, V2, or V3)
after QRS width normalization. All patients actually received a
dose of 1mg/kg of ajmaline. At the rate of 1mg/s, conduction
slowing and/or ventricular proarrhythmic effect appear in our
experience between 2 and 4min after starting the infusion and
never before 90 s. This means that the full dose of ajmaline (max
100mg) is actually given when its effects begin on ECG.
A proband was defined as the first case of Brugada ECG diag-
nosed within the family. Familial history of SCD, BrS, or ARVD/C
was defined accordingly to international criteria (McKenna et al.,
1994; Antzelevitch et al., 2005). Family history of BrS was defined
by the presence of one of the following findings documented at
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the time of inclusion: sudden cardiac death of a first degree rel-
ative under the age of 45 years; documented coved-type ECG in
family members (spontaneous or induced).
ELECTROPHYSIOLOGY (BrS GROUP)
Thirty-seven patients underwent signal-averaged ECG (SA-ECG,
high-pass filter of 25Hz and/or 40Hz, low-pass filter of 250Hz).
Ventricular late potentials were defined by the presence of ≥2 of
the 3 ESC/AHA/ACC criteria (filtered QRS > 114ms at 40 and
25Hz; LAS > 38ms at 40Hz, LAS ≥ 32ms at 25Hz; RMS40 <
20μV at 40Hz, RMS40 ≤ 25μV at 25Hz) (Gomes et al., 1987;
Breithardt et al., 1991).
Electrophysiological study, performed in all but one patient
(n = 50), included basal measurement of HV interval (n = 36)
and programmed ventricular stimulation (PVS, n = 50) without
antiarrhythmic drugs. PVS had to be performed after angiogra-
phy during the same hospitalization, or at least one month before
angiography to avoid functional wall motion abnormalities due to
fast pacing or recent electrical cardioversion. PVS was applied at
two sites [apex and RV outflow tract (RVOT)], at two drive cycle
lengths (600 and 400ms), using a maximum of three extrastim-
uli with a minimum coupling interval of 200ms. Patients were
inducible if a sustained (>30s) or syncopal ventricular arrhyth-
mia occurred [VF, polymorphic ventricular tachycardia (VT),
or monomorphic VT (Priori et al., 2002; Antzelevitch et al.,
2005)].
NON-INVASIVE IMAGING (BrS GROUP)
Among BrS group, all included patients had normal 2-
dimensional echocardiography. Mean LVEF was 64 ± 5% in BrS
group. Moreover, 32 patients underwent biventricular phase
angioscintigraphy and 29 patients underwent cardiac magnetic
resonance imaging (MRI).
CARDIAC CATHETERIZATION
All patients underwent right and left heart catheterization, and
coronary angiography performed by the same operator. Fluid-
filled pressures and pulmonary artery thermodilution cardiac
output were assessed (Swan-Ganz catheter, Abbott, Chicago,
Illinois). RV angiography was performed through a 145◦ 6F
angled pigtail catheter positioned at the RV apex, beyond
the moderator band. Left heart catheterization was performed
through a straight 6F pigtail catheter (Cordis, Roden, The
Netherlands). All patients had normal coronary angiograms.
RV and LV cineangiograms were recorded using two succes-
sive orthogonal views (RAO45◦ and LAO45◦ without angulation).
We chose these specific projections for better measurement of
TAPSE and crista supraventricularis shortening in the RAO pro-
jection and septal morphology in LAO projection, whatever RV
dilation (Hébert et al., 2004). Image calibration used a 40mm
metal ball. Images were analyzed by two independent trained car-
diologists (JLH, GD) using dedicated software (Philips Research
Laboratory, Suresnes, France).
Based on ESC/WHF 2000 criteria (Marcus et al., 1982;
McKenna et al., 1994; Corrado et al., 2000) and Hébert et al. work
(Hébert et al., 2004), RV structural abnormalities were defined by
hypertrophic trabeculae ≥4mm (“deep fissuring” of the anterior
wall), areas of negative contrast in the trabecular zone and/or
the moderator band (polycyclic images), apical aneurysm often
associated with Y-shaped negative contrast image, large bulging
or multiple outpouchings of the diaphragmatic wall, diastolic
bulging of the subtricuspid area, RVOT aneurysm as well as RV
free wall bulging in LAO projection.
Biventricular segmental motion was assessed by a modified
quantitative Sheehan centerline method (Hébert et al., 2004)
(100 clockwise chords, segmental shortening expressed in mm
in both projections). For each projection, segmentation of RV
and LV was manually performed and corresponded to a well-
defined anatomical zone (Figures 1, 2, 4). The mean excursion
was then automatically averaged for each segment and expressed
in millimeters ± one standard deviation (SD), and transposed on
a comparative nomogram for each projection, showing individ-
ual chord shortening compared to mean values (mean ± 1 SD)
obtained in control patients (Figure 2). Biplane volume calcu-
lations (mL) were performed according to Boak’s hemielliptical
model for the RV, and to Dodge’s ellipsoidal model for the LV
(Hébert et al., 2004).
GENETIC ANALYSIS
DNAwas extracted from peripheral blood lymphocytes according
to standard procedures, after having obtained the written consent
of the patients. SCN5A gene analysis was performed in 35 patients
from BrS groups I and II (without ARVD/C). All BrS group III
patients underwent a more extensive genetic study, which com-
prised analysis of SCN5A but also of genes coding for desmosomal
proteins, including PKP2, DSP, DSG2, and DSC2. We did not
analyze RyR2, JUP, and TGFβ3 with respect to the clinical pre-
sentation of the patients (absence of catecholaminergic VT or
palmo-plantar hyperkeratosis), and because of the controversial
role of RyR2 in the pathogenesis of ARVD/C.
As MOG1 (Multi-copy suppressor Of GSP1 mutants) was
recently described as a partner of Na(v)1.5, playing a poten-
tial role in the regulation of its expression and trafficking
(Kattygnarath et al., 2011), we decided to study the prevalence
of MOG1 mutation in our population. Mutations in the TRPM4
gene (Transient Receptor Potential channel (type 4) belonging to
the Melastatin subfamily). TRP channels have been identified as a
cause of an autosomal dominant form of cardiac conduction dis-
ease. As BrS patients or relatives often present with conduction
disturbances (atrio-ventricular block, sick sinus syndrome, fasci-
cular block), we decided at the time of the study to consider also
TRPM4 as a candidate gene for BrS (Stallmeyer et al., 2012).
All coding exons of the genes SCN5A, MOG1, TRPM4 and
PKP2, DSP, DSG2, DSC2 were amplified by polymerase chain
reaction (PCR) with specific primers and directly sequenced in
both strands. Direct sequencing was performed with the use of
the Big Dye dideoxy-terminator chemistry (Perkin Elmer) on
ABI 3830 DNA sequencer (PE Applied Biosystems, Foster, CA).
A mutation was defined by the presence of an abnormal vari-
ant which has not been described in previously published series,
which was absent in a panel of 300 controls (600 alleles) and
which was located in a highly conserved region through ani-
mal species. When available, cosegregation within the family was
considered as the last clue to confirm a mutation.
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FIGURE 2 | Quantitative angiographic analysis of segmental right
ventricular (RV) excursions in a 45◦ right anterior oblique projection
(patient 43, BrS group III, ARVD/C with BrS-ECG). (A) RV cineangiogram
at end diastole: trabecular hypertrophy (>4mm) and disarray which is
predominant at the apical part of the RV (white arrow). (B) RV end diastolic
(red) and end systolic (green) contours showing an akinetic
infundibulotrabecular junction (i.e., high RVOT), a hypokinetic anterior wall, a
dyskinetic apex (black arrow), a normal inferior contraction and a hypokinetic
sub-tricuspid segment. TAPSE, RV volumes, and RVEF were normal.
(C) Segmental excursions are plotted (blue line, bold) on a nomogram in a
clockwise direction from the high RVOT to the TAPSE and the crista
supraventricularis. Normal excursion values are represented by the red zone
(the white line represents the mean values of control patients and the red
zone corresponds to +1 SD or −1 SD).
STATISTICAL ANALYSIS
Quantitative data are expressed as mean ± SD and percent-
ages. We used a Student’s unpaired t-test for comparison of
quantitative data and an exact Fischer’s test for percentages.
For multiple comparisons we performed a variance analy-
sis (ANOVA), followed by a Student’s unpaired t-test, and
balanced by the Bonferroni correction. Qualitative data were
compared using χ2 test. A p-value <0.05 was considered
significant.
RESULTS
POPULATION
We included 51 patients in the BrS group (7 females, 44 males,
mean age 43 ± 11 years), 49 patients with localized ARVD/C
and no ST-segment elevation in the right precordial leads (14
females, 35 males, mean age 39 ± 13 years), and 14 control
patients (7 females, 7 males, mean age 38 ± 16 years). The main
results regarding the BrS group population are summarized in
Tables 1, 2. Sex ratio M/F was significantly higher in the BrS
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group compared to patients with localized ARVD/C without ST
abnormalities and to control patients (respectively 6.3 vs. 2.5
and 1, p = 0.0001, Table 3). This difference remained significant
when comparing localized ARVD/C without ST abnormalities,
either with a BS population pooling together BrS group I and BrS
group II (i.e., BrS-ECG and no ARVD/C) or with the BrS group
III (sex ratios M/F respectively of 2.5 vs. 5.8 and 9, p = 0.0001).
Among BrS group, 19/51 patients (37%) presented with a
spontaneous BrS type 1 ECG. The remaining 32 had a base-
line BrS type 2 or 3 ECG, converted to type 1 under ajmaline
infusion. Familial screening of BrS concerned only 5 patients of
our series, whereas the remaining 46 were probands. Nineteen
patients (37%) were symptomatic for aborted sudden death, ago-
nal nocturnal respiration or syncope. Two patients presented with
aborted SCD (documented nocturnal VF), 2 others with noctur-
nal seizures and syncope history, and 15 with at least one syncopal
episode. Among patients without aborted sudden death, agonal
nocturnal respiration or syncope, 2 patients presented palpita-
tions and dizziness, 6 complained of lipothymia, and 5 others of
palpitations. Remarkably, 12/34 patients (24%) had atypical chest
pain, which was the cause of achieving an ECG in 10 patients. For
the remaining 9 asymptomatic patients (18%), BrS-ECG diagno-
sis was fortuitous (systematic ECG). At the time of inclusion, 3
patients had an ICD because of type 1 ECG associated with his-
tory of aborted SCD, nocturnal agonal respiration or syncope.
There was no statistical difference in terms of symptoms (syn-
cope, SCD, seizures) between patients regarding the BrS-ECG
type (1, 2, or 3) (p = 0.5). Moreover, no statistical significant dif-
ference was observed between BrS groups I, II, and III, in terms of
symptoms (atypical chest pain, syncope or pre-syncope, seizures,
SCD, p = 0.08).
PRIMARY OUTCOME (TABLES 1, 2)
Among BrS group, 34/51 patients (67%) fulfilled BrS HRS/EHRA
2005 criteria (Antzelevitch et al., 2005), mainly because 19/51
(37%) were symptomatic with aborted sudden death, agonal noc-
turnal respiration or syncope, because of a positive ventricular
stimulation in 14 patients (28%) or because of a familial history
of SCD before the age of 45 years in 10 patients (20%). Among
BrS group III, 8/10 patients (16% of all the BrS-ECGs) fulfilled
international ESC/WHF 2000 ARVD/C criteria (McKenna et al.,
1994; Corrado et al., 2000) and 5/10 (10% of all the BrS-ECGs)
fulfilled BrS HRS/EHRA 2005 diagnostic criteria. An overlap was
observed in 4 patients (8% of all the BrS-ECGs) who fulfilled both
ARVD/C and BrS international criteria.
NON-INVASIVE ELECTROPHYSIOLOGY (BrS GROUP)
Systematic ECG recording in one upper space above the usual
right precordial leads (3rd intercostal space for V1H (V1 “high”)
and V2H , 4th intercostal space for V3H) showed a BrS type 1 ECG
in 63% of the cases (n = 26, Figure 3) and allowed the diagnosis
of BrS-ECG in 34% (n = 14, where a coved-type pattern was only
visible in one of the classical leads V1, V2, V3, but also in one or
more of the leads V1H, V2H, V3H). Reversible conduction slowing
was observed in 24% of the cases (n = 10, mainly PR interval and
QRS duration (>30%) prolongation). No further complication
occurred.
Baseline ECG showed a prolonged PR interval (≥200ms)
in 7 patients (14%), a left anterior fascicular block (QRS axis
beneath −30◦) in 7 patients (14%) and a left posterior fascicular
block in one patient (patient 28, BrS group II, with a PR inter-
val of 200ms). Remarkably, a left anterior fascicular block was
present in 2 patients with ARVC/D (BrS group III) as compared to
5 patients (p = NS) without ARVD/C [BrS (I+II) groups]. A pro-
longed PR interval alone was present in 2 patients with ARVD/C
(BrS group III) and in 4 patients without ARVD/C [BrS group
(I+II), p = NS].
Holter-ECG or continuous monitoring showed premature
ventricular contractions in 12/51 patients (24%), with a left bun-
dle branch block pattern in 9, and associated with non-sustained
RVOT tachycardia in one patient from BrS group III (n = 42).
SA-ECG was performed in 37/51 patients from BrS group
(73%) at 40 and/or 25Hz. When combining the results of SA-
ECG at 40 and/or 25Hz, late potentials were present in 27 patients
out of 37 (73%). The presence of late potentials (at 40 and/or
25Hz) was associated with a sensitivity of 100%, a specificity of
37%, a positive predictive value (PPV) of 37% and a negative pre-
dictive value (NPV) of 100% for angiographic ARVD/C diagnosis
(BrS group III). Late potentials were significantly more frequent
at 40Hz and at 40 and/or 25Hz in BrS group III compared to
patients with a BrS-ECG and no ARVD/C [BrS groups (I+II),
χ2 test, p = 0.04 and p = 0.02 respectively, p = 0.06 for 25Hz
alone].
INVASIVE ELECTROPHYSIOLOGICAL STUDY (BrS GROUP)
Mean HV interval was 48 ± 7ms (range 38–65ms). Mean RV
effective refractory period was 226 ± 20ms. A sustained/syncopal
VF or polymorphic VT was induced in 28% of the cases (n = 14),
while non-sustained polymorphic VT was induced in 7 addi-
tional patients. We found no difference concerning inducibility
between BrS groups I, II, and III, neither between asymp-
tomatic and symptomatic patients, nor between patients with
or without spontaneous type 1 BrS-ECG. Finally, one of the
2 patients who experienced previous SCD was not inducible
(n = 25).
NON-INVASIVE IMAGING (BrS GROUP)
Cardiac MRI was performed in 29 BrS patients. Overall, MRI
abnormalities (mainly localized RV wall motion abnormalities)
were seen in 45% (13/29) of BrS patients, with fatty infiltration
in 17% (5/29), which was often considered as non-specific by
radiologists.
Radionuclide angiography was performed in 32 BrS patients.
Mean RVEF was 52 ± 7% and mean LVEF was 64 ± 5% (ver-
sus contrast angiography, p = NS and p = 0.03, respectively).
We noticed in 25% of the 32 explored cases (n = 8) a RVOT
phase delay and a localized RV hypokinesia in 13% (n = 4). Seven
patients from BrS group III underwent angioscintigraphy, which
confirmed in two cases the diagnosis of ARVD/C made with con-
trast angiography (marked localized hypokinesia associated with
a RVOT phase delay). Despite a poor sensitivity for ARVD/C
diagnosis, angioscintigraphy had an excellent PPV (100%) and a
good NPV (86%) as compared to contrast angiography (Table 3,
bottom).
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FIGURE 3 | Two typical BrS-ECGs (speed 25mm/s; gain 1mm/mV).
Top: patient 33 with a baseline type 1 Brugada ECG (BrS group I). Bottom:
patient 43 with a spontaneous type 1 Brugada ECG (left panel), becoming
caricatural after ajmaline infusion (right panel, BrS group III, ARVD/C). V1H,
V2H, V3H mean upper space above the right precordial leads V1, V2, and V3,
respectively.
CARDIAC CATHETERIZATION
Hemodynamical study (Table 3)
All groups under study were comparable in terms of right or left
heart pressures, pulmonary or systemic vascular resistances (PVR,
SVR), arteriovenous oxygen content difference, or hemoglobin
content. The significant difference in heart rate observed between
BrS group and patients with localized ARVD/C without ST seg-
ment elevation was attributed to the frequent prescription of
β-blockers in the last group (76 ± 14 vs. 69 ± 14 bpm, p =
0.009). Cardiac index was significantly higher in patients from
the BrS group compared to patients with localized ARVD/C
without ST abnormalities (3.9 ± 0.8 vs. 3.3 ± 0.8 L/min/m2, p =
0.003). This was also the case when comparing BrS group III
(ST-syndrome and ARVD/C) with localized ARVD/C without
ST abnormalities (3.9 ± 0.7 vs. 3.3 ± 0.8 L/min/m2, p = 0.01).
This finding could be also attributed to the lower heart-rate
of this group. We observed no significant difference in terms
of cardiac index between BrS groups I, II, III, and control
patients.
Digitized quantitative contrast angiography
Qualitative analysis. The 26 patients from BrS group II (with-
out overt structural abnormalities) had three different types
of segmental wall motion abnormalities (Figure 4): (1) diffuse
anterior RV hypokinesia or akinesia (n = 15), corresponding
to an extended anteroapical RV hypokinesia, sometimes asso-
ciated with an inferior RV hypokinesia (n = 9); (2) localized
apical RV hypokinesia or akinesia (n = 7); and (3) hypokinesia
or akinesia restricted to the anterior RV infundibulo-trabecular
junction (n = 4). BrS group III patients (n = 10) had RV struc-
tural abnormalities (deep fissuring) corresponding to early or
localized ARVD/C, predominantly affecting the RV anteroapical
wall (Figures 1, 2).
LV anatomy was comparable between BrS groups I, II, and
III. None of the patients had RV or LV microaneurysms (Frustaci
et al., 2005).
Quantitative assessment of RV systolic function (Table 3). The
RVEF and TAPSE were comparable between BrS groups I, II, and
III, as well as between BrS group and control patients. However,
RVEFwas significantly higher in BrS group compared to ARVD/C
patients without ST segment elevation (57 ± 5 vs. 54 ± 5%, p =
0.006). This difference was related to a higher RVEF among
patients with a BrS-ECG and no ARVD/C (BrS groups I+II, n =
41) compared to ARVD/C patients without ST segment elevation
(58 ± 5 vs. 54 ± 5%, p = 0.004). RVEF was comparable between
the BrS group III and ARVD/C patients without ST segment
elevation (56 ± 5 vs. 54 ± 5%, p = NS).
Statistically significant differences in terms of segmental excur-
sion between BrS groups I, II and III were seen for the anterior,
apical (BrS group I vs. II, BrS group I vs. III) and inferior
(BrS group I vs. II) walls of the RV. On one hand, there was
no difference in terms of RV segmental excursion between BrS
groups II and III. On the other hand, only localized ARVD/C
(with or without BrS-ECG) provided anteroapical dyskinesia.
The excursion of the mid-lateral wall was significantly larger in
patients with a BrS-ECG and no ARVD/C (BrS groups I+II), as
compared to control patients and ARVD/C patients without ST
segment elevation (12.6 ± 3.3 vs. 10.3 ± 3.0 and 10.6 ± 3.8mm,
p = 0.02).
Quantitative assessment of LV systolic function (Table 3). The
LVEF was comparable between BrS groups I, II, and III, and
between BrS group and control patients.
No complication occurred during follow-up.
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FIGURE 4 | Three typical examples of right ventricular (RV) segmental
wall motion abnormalities observed in BrS group II. (A) Akinesia
restricted to the RV apex (bold black arrow). (B) Hypokinesia or outpouching
without dyskinesia of the anterior infundibulo-trabecular junction (bold black
arrow). (C) Diffuse anteroapical hypokinesia with anteroapical akinesia (four
bold black arrows), inferior and sub-tricuspid hyokinesia (thin black arrow).
GENETICS
The results of our genetic study (n = 45) are reported in Tables 1,
2. A missense R965C SCN5A mutation was found in one patient
(patient 41, BrS group II), resulting in a single amino-acid substi-
tution. A Black african male (patient 33) belonging to BrS group
I carried an African SCN5A polymorphism (R481W) concerning
a highly preserved gene segment among 5 species and 300 con-
trols, which has been described in a recent publication as a special
polymorphism (Tan et al., 2005). He had also a double polymor-
phism ofDSG2 andDSC2. Patient 37, native of Cambodia, carried
a TRPM4 mutation p.Q131H (c.393G>C) and had a baseline
incomplete right bundle branch block, associated with a type 3
BrS-ECG and a left anterior fascicular block.
Among the 10 patients from BrS group III who underwent
a more extensive genetic study, no desmosomal gene mutation
was found. Patient 43 carried a rare PKP2 polymorphism (mis-
sense, A264V) and patient 44 carried a DSG2 polymorphism
(p.Ser882Pro, c2644T>C). No SCN5A mutation was found in
this group (Table 2, bottom). Another PKP2 polymorphism was
found in patient 24 (BrS group II).
DISCUSSION
BrS is an important cause of SCD among young people, partic-
ularly in men, like hypertrophic cardiomyopathy and ARVD/C
[BrS represents 4 to 10% of all SCD and 20% of SCD with a nor-
mal heart (Antzelevitch et al., 2005)]. In their first report, Brugada
and Brugada described eight cases without echocardiographic
or angiographic abnormalities (Brugada and Brugada, 1992). In
later studies however, the absence of structural abnormalities was
presumed from routine echocardiography and MRI, which have
a poor sensitivity for the diagnosis of focal ARVD/C, myocardi-
tis (microaneurysms) or early stage of cardiomyopathy, all able
to mimic a BrS (Frustaci et al., 2005). The main objective of the
present study was to look for a potential overlap between BrS and
ARVD/C by assessing prospectively their respective prevalence on
the basis of international criteria, in patients with BrS-ECG and
Frontiers in Physiology | Cardiac Electrophysiology December 2012 | Volume 3 | Article 474 | 12
Duthoit et al. Digitized cineangiography and Brugada ECG pattern
normal echocardiography. This question is important in daily
practice when a patient is referred for BrS or BrS-ECG evaluation
and management. Therapeutic options remain indeed challeng-
ing in the setting of a BrS-ECG pattern associated with ARVD/C
as arrhythmias are usually triggered by exercise in ARVD/C and
by vagal tone and rest in BrS, but also because anti-arrhythmic
drugs such as all Ic class (flecainide) and beta-blockers are pro-
tective in ARVD/C while contra-indicated (class Ic) or not logical
in BrS (isoproterenol is useful for electrical stormmanagement in
BrS) (Postema et al., 2009).
MAIN FINDINGS
In our series, the primary endpoint was achieved in 4/51
patients (8%) with a BrS-ECG who fulfilled both ESC/WHF 2000
ARVD/C criteria and HRS/EHRA 2005 BrS criteria, despite a
normal echocardiography.
Among BrS group, 34/51 patients (67%) fulfilled BrS
HRS/EHRA 2005 criteria, and 8/51 (16%) fulfilled ESC/WHF
2000 ARVD/C criteria. Contrast angiography showed RV wall
motion abnormalities in 36/51 patients (71%). Among these
patients, 26 (51%) had RV wall motion abnormalities without
structural alterations (i.e., deep fissuring, BrS group II), and 10
(20%) presented structural alterations compatible with localized
(anteroapical and/or diaphragmatic) ARVD/C (BrS group III).
Only 15 (29%) patients had a strictly normal RV at angiography.
To our knowledge, this is the first study that showed prospec-
tively an overlap between BrS and ARVD/C. This notion of an
overlap may suggest that some patients of our series belonging
to BrS group II (i.e., segmental wall motion abnormalities with-
out ARVD/C) could present a potential or subclinical ARVD/C,
as it is the case among BrS group III patients. In our opin-
ion, three assumptions can be made to explain this overlap: (1)
the existence of functional abnormalities of myocardial contrac-
tion due to impaired depolarization [i.e., late activation (Coronel
et al., 2005; Nademanee et al., 2011) and incomplete right bun-
dle branch block] and impaired repolarization associated with
BrS [i.e., transmural voltage gradient due to loss of the epicar-
dial action potential dome (Yan and Antzelevitch, 1999)]. This
hypothesis could be applied in cases of diffuse RV hypokinesis
(anteroapical and inferior) or in case of localized high RVOT (i.e.,
infundibulotrabecular junction) bulging seen onMRI or contrast
angiography; (2) the second hypothesis relies on the fact that
structural abnormalities (including fibrosis and fatty infiltration)
have been reported in association with BrS and/or mutations in
the cardiac sodium channel, as were able to demonstrate Coronel
et al. (Coronel et al., 2005). This might be the case in the pres-
ence of segmental RV akinesia or concealed ARVD/C and could
be attributed to an excitation failure of the myocardium, in par-
ticular epicardial; and (3) RV conduction disturbances observed
in BrS may explain a delayed onset of RV contraction, besides
increasing RVwall stress (current-to-load mismatch) which could
be responsible of the RV structural abnormalities over time
(Coronel et al., 2006; Hoogendijk et al., 2010).
ELECTROPHYSIOLOGY
Ajmaline testing is recognized as the best method to unmask BrS-
ECG. Its sensitivity, although imperfect, ranges from 80 to 100%
among series (Priori et al., 2000; Hong et al., 2004; Wolpert et al.,
2005), which is far better than with flecainide acetate (68%). For
Hong et al. (Hong et al., 2004), ajmaline testing has a good sen-
sitivity and PPV to identify SCN5A mutations (94.4 and 93.3%,
respectively), making us confident in the diagnosis of BrS in
our series.
Late potentials were present in 73% of the patients (27/37) of
our BrS series. These results are concordant with Kim et al. series
(82%) (Kim et al., 2006). Late potentials were present in 63%
(17/27) of patients without ARVD/C (groups I and II) and in 60%
(12/20) of patients without ARVD/C and fulfilling HRS/EHRA
diagnostic criteria for BrS. Their presence does not appear spe-
cific of BrS with RV segmental wall motion abnormalities or of
an organic RV disease like ARVD/C. Late potentials on SA-ECG
have been related to the presence of epicardial diastolic (late)
potentials located to the anterior wall of the RVOT (Nagase et al.,
2002). For Antzelevitch et al., their presence could be the func-
tional consequence of an epicardial notch accentuation associated
with a loss of the action potential’s dome (Antzelevitch, 2002),
but other authors (Coronel et al., 2005) have shown the pres-
ence of a delayed endocardial conduction through the RVOT,
in the absence of a transmural gradient, but in the presence
of localized interstitial fibrosis, i.e., organic. These observations
support the hypothesis of an arrhythmogenic substrate located
to the RVOT. Indeed, Nademanee et al. have demonstrated that
the arrhythmic underlying electrophysiological mechanism in
patients with BrS was delayed (>100ms) depolarization over the
anterior aspect of the RVOT epicardium, showing low voltage
(<1mV), prolonged (>130ms) and fractionated late potentials.
Catheter ablation over this abnormal area resulted in normaliza-
tion of the BrS-ECG and prevented further VT/VF recurrence
(Nademanee et al., 2011). In our series, SA-ECG was useful to
exclude the diagnosis of localized ARVD/C associated with a
BrS-ECG, with a sensitivity of 100% and NPV of 100%, despite
poor specificity and PPV (at 40 and/or 25Hz, positive if ≥2
criteria).
The low rate of inducible patients during PVS in our series
(28%), compared to previously published series reporting an
inducibility ranging from 36 (Kim et al., 2006) to 67% (Priori
et al., 2000), can be explained by the broad proportion of pauci-
symptomatic patients in our series, but also by the poor sensitivity
and reproducibility of this tool, which has been shown even
in survivors of VF (Priori et al., 2000; Eckardt et al., 2005).
The prognostic value of the PVS seems limited, particularly in
patients at low or intermediate risk like in our series, since it is
known that the association of a BrS type 1 ECG with a history
of spontaneous syncope is the major determinant of prognosis
in the BrS (Priori et al., 2000; Eckardt et al., 2005; Probst et al.,
2010).
CARDIAC IMAGING AND HEMODYNAMICS
The presence of angiographic morphological abnormalities in
71% of cases in this series confirms the relevance of a biven-
tricular invasive study as part of the initial assessment of BrS,
yet rarely achieved in this indication. Our results also empha-
sizes the inability of standard echocardiography to identify early
stages of cardiomyopathies like localized ARVD/C, but also the
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limitations of cardiac MRI (Frustaci et al., 2005) or radionuclide
angiography in these indications (false positives for MRI, lack
of sensitivity for MRI and radionuclide angiography). However,
Takagi et al. (Takagi et al., 2001) were the first to demonstrate
in vivomorphological MRI abnormalities of the RV in BrS, show-
ing hypokinesia, akinesia or localized aneurysms, which were
present in 81% of cases. Recently, Catalano et al. found with
MRI a high prevalence (50 vs. 17% for controls) of mild RV
wall motion abnormalities among patient with BrS associated
with a reduction in RVOT ejection fraction, an enlargement of
the RV inflow diameter, and a mild increase in RVESV (not
RVEDV) without fatty infiltration (Catalano et al., 2009). These
data together with other observations support the fact that mor-
phological and histological abnormalities are very common in BrS
(Frustaci et al., 2005; Kim et al., 2006; Zumhagen et al., 2009).
They may take the form of simple RV wall motion abnormal-
ities, of moderate changes such as hypertrophy, mild fibrosis,
and fatty infiltration, but also of genuine early or localized car-
diomyopathies (documented by endocardial biopsies by Frustaci
et al.), which may include ARVD/C, myocarditis or a latent form
of cardiomyopathy.
With quantitative digitized contrast angiography, we con-
firmed in vivo the postmortem observations of Corrado et al.
(Corrado et al., 1996, 2001) which showed that the clinical forms
of ARVD/C associated with a Brugada ECGwere exclusively local-
ized or focal, affecting the antero-apical wall of the RV and
taking the aspect of a predominantly fatty ARVD/C. Moreover,
the hemodynamic profile of our patients and the functional
angiographic analysis suggest that ARVD/C associated with a BrS-
ECG may correspond to an earlier phase of ARVD/C disease as
compared to localized forms of ARVD/C without ST segment
elevation in the right precordial leads.
GENETIC STUDY
The prevalence of a SCN5A mutation in our series was partic-
ularly low [2.2% in our series, as compared to 15–25% in the
literature (Ackerman et al., 2011)]. This might be explained by
the low prevalence of family history of BrS/SCD in our series
(12/51, 23%). However, BrS-ECG was well characterized. This
could also be due to the fact that the population under study
is made of patients with a BrS-ECG pattern, without evidence
for an overt structural heart disease (on echocardiogram), but
whichmay include early forms of cardiomyopathies like ARVD/C,
myocarditis, both mimicking BrS-ECG, or pure BrS.
One patient was initially thought to have a R481W mutation
that has proven to be retrospectively a rare African polymor-
phism. However, this particular polymorphism could be not
benign as its presence induces in vitro sodium current altered elec-
trophysiology. Tan et al. showed (Tan et al., 2005) that the R481W
polymorphic channel found in Blacks and Hispanics produced a
significantly slower sodium current recovery from inactivation in
both splice variant backgrounds and increased slow inactivation
in Q1077del background compared with wild-type. Also, R481W
showed a significantly negative shift of inactivation midpoint in
Q1077del background. Shifts of a similar magnitude have been
reported for arrhythmia syndrome mutations and are thought to
be pathogenic.
Candidate gene analysis for MOG1 was disappointing as no
patient out of 41 screened carried a mutation, even if it has
been showed that dominant-negative mutations in MOG1 can
impair the trafficking of Na(v)1.5 to themembrane, leading to INa
reduction and clinical manifestation of BrS (Kattygnarath et al.,
2011). The presence of a previously published TRPM4 mutation
(patient 47, p.Q131H, c.393G>C) suggests a relationship between
progressive conduction diseases and BrS (Stallmeyer et al., 2012).
Given our analysis of genes encoding proteins of the cardiac
desmosome in patients with BrS and RV structural abnormali-
ties compatible with ARVD/C, we would not recommend to test
PKP2, DSP, DSG2, and DSC2 genes routinely in BrS. However,
genetic testing is negative in 30–70% of overt forms of ARVD/C
(Ackerman et al., 2011) and new candidate genes implicated in
ARVD/C pathogenesis could be still good candidates for genetic
screening in BrS. The absence of gene mutation in our patients
with BrS-ECG and ARVD/C could also suggest the existence of a
new entity, distinct from pure BrS and from ARVD/C itself, which
could be genetic or acquired (such as myocarditis sequelae for
example).
Our results underline the limited role of a systematic genetic
screening in BrS and the debated causative role of SCN5A muta-
tion in BrS (Coronel et al., 2006). Genetic testing has been
recently recommended by HRS/EHRA experts for family mem-
bers and appropriate relatives following the identification of
the BrS-causative mutation in an index case; SCN5A mutation
screening can be useful for any patient in whom a cardiologist has
established a clinical index of suspicion for BrS; genetic testing
is not indicated in the setting of an isolated type 2 or 3 BrS-
ECG (Ackerman et al., 2011). Nevertheless, pathophysiology of
BrS is complex and some authors as Coronel et al. and Frustaci
et al. have reported three authentic SCN5A mutations associated
with histological and/or angiographic findings consistent with
ARVD/C in patients with BrS (Coronel et al., 2005; Frustaci et al.,
2005), raising again the question of an overlap between BrS and
localized forms ARVD/C (Perez Riera et al., 2005; Hoogendijk
et al., 2010).
STUDY LIMITATIONS
Given that quantitative contrast angiography remains a gold-
standard in ARVD/C, we do not currently have another available
technique to assess the diagnostic accuracy of contrast angiogra-
phy, apart from the histological examination of endomyocardial
biopsies. These biopsies were not performed in the present series
for safety reasons and for their poor diagnostic yield.
Genetic analysis was incomplete in this series as 6 patients
without ARVD/C (6/41) refused genetic screening and as only
4 patients without ARVD/C underwent a finally negative screen-
ing of PKP2, DSP, DSG2, andDSC2 genes. Patients with ARVD/C
and BrSmay also present large genomic deletions, large insertions
or genomic rearrangement, as we did not dispose at the time of
the study of Multiplex Ligation-dependent Probe Amplification
(MLPA) technique.
CONCLUSIONS
In our series, 71% of the 51 consecutive patients with a BrS-ECG
and a normal echocardiography had abnormal RV wall motion
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and 16% had structural alterations corresponding to localized
(anteroapical and/or diaphragmatic) ARVD/C at angiography.
Moreover, 8% of patients with a BrS-ECG fulfilled both BrS
and ARVD/C international criteria. Our results strongly support
the hypothesis of an overlap between BrS and localized or con-
cealed forms of ARVD/C, but also that Brugada ECG pattern
is not specific of a pathophysiological entity, i.e., BrS, but can
be due to other conditions such as myocarditis or localized RV
cardiomyopathy.
In patients with such an overlap, and based on our experience,
we would recommend to avoid Class Ic antiarrhythmic drugs
prescription, automedication and fever (by the use of paraceta-
mol or aspirin) as for any BrS patient. If ventricular arrhythmias
are present, hydroquinidine and/or beta-blockers use could be
considered, under careful ECG and Holter-ECG monitoring.
ICD implantation indications should follow current available
guidelines.
We believe that a BrS ECG pattern may be an indicator of
ARVC, particularly in its clinically concealed phase, thus requir-
ing morphological RV evaluation, such as MRI, contrast echocar-
diography and/or contrast angiography. One of the explanations
of the low prevalence of SCN5Amutations in our series may lie in
the high proportion of structural abnormalities and of localized
ARVD/C. Several reasons may explain that difference as com-
pared to other series: (1) most of the Brugada series did not assess
the RV morphology with more than a standard echocardiogram,
which is of particularly limited interest for RV study; (2) very few
authors performed digitized contrast angiography in BrS; and (3)
among the 10 patients who happened to have RV morpholog-
ical abnormalities compatible with ARVD/C, none presented a
desmosomal mutation, which is atypical. This overlap between
BrS and ARVD/C does not mean that these two diseases are the
same one, but that a substantial proportion of patients with a
Brugada ECG pattern present RV structural alterations.
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